<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02081339</url>
  </required_header>
  <id_info>
    <org_study_id>E2038</org_study_id>
    <nct_id>NCT02081339</nct_id>
  </id_info>
  <brief_title>Cohort Study of the Clinical Course of Macular Diseases in Japanese</brief_title>
  <official_title>Cohort Study of the Clinical Course of Macular Diseases in Japanese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto University, Graduate School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto University, Graduate School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent clinical introduction of anti-vascular endothelial growth factor agents may change the
      clinical course of macular diseases, including age-related macular degeneration (AMD),
      polypoidal choroidal vasculopathy (PCV), retinal angiomatous proliferation (RAP), central
      serous chorioretinopathy (CSC), myopic choroidal neovascularization (CNV), retinal vein
      occlusion (RVO), diabetic macular edema (DME), and so forth.

      Patients with such macular diseases are registered and and are followed up for 5 years with
      appropriate treatment for each patient. By the analysis of the correlation between initial
      examinations and final visual acuity, factors associated with good visual prognosis will be
      elucidated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Initial factors associated with visual prognosis in each macular disease</measure>
    <time_frame>Five years after the registration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference in the visual prognosis depending on the treatments in each macular diseases</measure>
    <time_frame>Five years after the registration</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in visual acuity in each macular diseases.</measure>
    <time_frame>Five years after the registration.</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Macular Disease</condition>
  <arm_group>
    <arm_group_label>Macular diseases</arm_group_label>
    <description>ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/„é°</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ranibizumab, aflibercept, pegaptanib, verteporphin</intervention_name>
    <arm_group_label>Macular diseases</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who visit Department of Ophthalmology Kyoto University Hospital with macular
        diseases.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who visit Department of Ophthalmology Kyoto University Hospital with macular
             diseases.

          -  Patients who are agreed with the participation of this study.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nagahisa Yoshimura, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyoto University, Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Akitaka Tsujikawa, MD</last_name>
    <phone>+81-75-751-3260</phone>
    <email>tujikawa@kuhp.kyoto-u.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kyoto University Graduate School of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>606-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Misao Ogaki</last_name>
      <phone>+81-75-751-3248</phone>
      <email>misao@kuhp.kyoto-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Akitaka Tsujikawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2014</study_first_submitted>
  <study_first_submitted_qc>March 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2014</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto University, Graduate School of Medicine</investigator_affiliation>
    <investigator_full_name>Nagahisa Yoshimura</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
    <mesh_term>Verteporfin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

